Want to see SE:VIVE full AI Analyst Report?
Top Page
Vivesto AB
(VIVE)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr8.50
▲(10525.00% Upside)
Action:Reiterated
Date:05/27/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and a shrinking equity base with no recent reported revenue), partially offset by constructive technical momentum. Valuation remains unfavorable/indeterminate due to negative earnings and no stated dividend yield.
Positive Factors
Platform & partnering model
Vivesto's proprietary drug-delivery platforms and explicit partnering/licensing focus are durable strategic assets. A licensing-led model can scale R&D returns, limit commercialization capex, and monetize assets via milestones and royalties, supporting long-term capital efficiency.
Negative Factors
Persistent net losses
Ongoing multi-year net losses materially erode retained capital and constrain internal funding for R&D. Persistent unprofitability increases reliance on external financing, heightens dilution risk, and lowers resilience to adverse trial or partnership outcomes over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & partnering model
Vivesto's proprietary drug-delivery platforms and explicit partnering/licensing focus are durable strategic assets. A licensing-led model can scale R&D returns, limit commercialization capex, and monetize assets via milestones and royalties, supporting long-term capital efficiency.
Read all positive factors
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr95.10M
Dividend YieldN/A
Average Volume (3M)410.92K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue GrowthN/A
EPS Growth21.82%
CountrySE
Employees4
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,071,369
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Vivesto AB Business Overview & Revenue Model
Company Description
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. I...
How the Company Makes Money
null...
Vivesto AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2022 | Dec 2021 | Apr 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.01M | 26.19M | 201.84M |
| Gross Profit | -1.04M | 0.00 | -3.19M | -10.66M | -17.93M | 215.84M |
| EBITDA | -31.33M | -34.38M | -36.56M | -89.76M | -97.62M | -11.50M |
| Net Income | -32.69M | -34.08M | -39.75M | -367.03M | -138.94M | -10.53M |
Balance Sheet | ||||||
| Total Assets | 177.85M | 149.04M | 172.88M | 355.88M | 594.31M | 863.54M |
| Cash, Cash Equivalents and Short-Term Investments | 31.48M | 2.10M | 32.29M | 142.51M | 97.27M | 287.40M |
| Total Debt | 0.00 | 13.00M | 0.00 | 8.17M | 10.43M | 0.00 |
| Total Liabilities | 11.29M | 24.46M | 14.55M | 30.45M | 44.59M | 176.80M |
| Stockholders Equity | 166.56M | 124.58M | 158.33M | 325.42M | 549.71M | -1.22B |
Cash Flow | ||||||
| Free Cash Flow | -36.17M | -43.81M | -47.25M | -80.79M | -179.91M | -211.41M |
| Operating Cash Flow | -37.34M | -33.96M | -47.25M | -80.52M | -145.56M | -204.86M |
| Investing Cash Flow | -11.13M | 21.85M | 43.40M | -45.28M | 118.65M | -21.55M |
| Financing Cash Flow | 48.94M | 13.00M | 0.00 | 128.76M | -5.81M | -6.01M |
Vivesto AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:VIVE
Vivesto AB
8.45
-11.74
-58.15%
DE:AC6
AlzeCure Pharma AB
0.57
0.38
191.37%
DE:5J2
Gabather AB
―
―
―
DE:6FN
Klaria Pharma Holding AB
0.06
0.03
93.94%
DE:40M
Nanexa AB
0.30
0.12
67.96%
SE:ERMA
Enorama Pharma AB
0.26
-2.17
-89.46%
Vivesto AB Corporate Events
Vivesto Sets Maximum Tolerated Dose in Feline Paccal Vet Cancer Study
Jul 1, 2026
Vivesto AB has completed patient recruitment in a dose-finding study of its veterinary cancer drug Paccal Vet in cats with solid tumors and established the maximum tolerated dose. The trial, which enrolled 21 cats across U.S. sites, is assessing s...
Vivesto completes dog cancer trial recruitment as Paccal Vet nears key data readout
Jun 26, 2026
Vivesto AB has completed recruitment in its open-label pilot study of Paccal Vet in dogs with splenic hemangiosarcoma following splenectomy, enrolling 18 to 19 evaluable animals across eight U.S. clinical sites. The trial administers up to four tr...
Vivesto completes dog enrollment in Paccal Vet hemangiosarcoma study ahead of Q3 data
Jun 26, 2026
Vivesto AB has completed recruitment of 18 evaluable dogs in its open-label pilot study of Paccal Vet, a paclitaxel micellar formulation, in U.S. dogs with splenic hemangiosarcoma following splenectomy. The study, conducted across eight clinical s...
Vivesto’s Cantrixil Clears Key Preclinical Hurdle With Positive i.v. Safety Data
Jun 16, 2026
Vivesto AB has reported positive results from an exploratory pharmacokinetic and toxicology study of its cancer drug candidate Cantrixil administered intravenously in dogs, marking the first such assessment in a larger animal species. Cantrixil wa...
Vivesto names seasoned life science financier Björn Svanström as new CFO
Jun 5, 2026
Vivesto AB, a Swedish oncology-focused developer of cancer treatments, is advancing a pipeline that includes the blood cancer candidate Cantrixil and the veterinary oncology program Paccal Vet, targeting dogs with splenic hemangiosarcoma and cats ...
Vivesto Cuts Share Count After 1-for-100 Reverse Split
May 29, 2026
Vivesto AB has completed a 1-for-100 reverse share split, consolidating every hundred existing shares into a single new share to restructure its capital base. Following this transaction, the total number of shares and voting rights in the company ...
Vivesto Sets Timetable for 1:100 Reverse Share Split
May 13, 2026
Vivesto AB has set 21 May 2026 as the record date for a 1:100 reverse share split approved at its recent annual general meeting, consolidating every 100 existing shares into one new share. Trading in the company’s stock will reflect the new ...
Vivesto AGM Backs Reverse Share Split and Capital Cut to Streamline Structure
May 7, 2026
Vivesto AB’s annual general meeting approved the 2025 financial statements, decided to carry forward profits without paying a dividend, and granted discharge from liability to the board and CEO, signaling continuity in governance. Shareholde...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.